View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
December 24, 2021updated 07 Jan 2022 6:21am

Coronavirus company news summary- Sinovac Covid-19 vaccine booster less effective against Omicron- South Africa approves Janssen Covid-19 booster shot

A booster dose of Sinovac Covid-19 vaccine following a two-shot regimen does not offer adequate protection against the fast spreading Omicron variant, a laboratory study has found. The study was conducted by a team of researchers from the University of Hong Kong and the Chinese University of Hong Kong, reported Reuters. The number of samples used in the study was not disclosed. The study also found that Pfizer-BioNTech vaccine was more effective in neutralising the Omicron variant.

The South African Health Products Authority (SAHPRA) has approved Covid-19 vaccine Janssen (Ad26.COV2.S) as a second dose or a booster following an assessment of safety and efficacy data. According to a SAHPRA statement, the Janssen vaccine can be administered as a booster shot minimum two months after primary vaccination with an approved mRNA vaccine. The authorisation comes after Janssen submitted an application earlier this month requesting an amendment in the dosing schedule for Janssen vaccine.

Novavax and SK bioscience have agreed to expand their collaboration and licence agreements for the former’s recombinant nanoparticle protein-based Covid-19 vaccine NVX-CoV2373. As agreed, SK bioscience will reserve additional manufacturing capacity to produce antigen, a key component of NVX-CoV2373 through next year. The arrangement may be extended in future. Previously, SK bioscience signed an advance purchase agreement (APA) to deliver 40 million doses of NVX-CoV2373 for South Korea.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology